Previous Article | Next Article ![]()
Infection and Immunity, September 2005, p. 6154-6156, Vol. 73, No. 9
0019-9567/05/$08.00+0 doi:10.1128/IAI.73.9.6154-6156.2005
Section of Retroviral Immunology,1 Division of Therapeutic Proteins, CBER/FDA, Bethesda, Maryland 208922
Received 28 February 2005/ Returned for modification 4 April 2005/ Accepted 19 April 2005
Synthetic oligodeoxynucleotides containing CpG motifs trigger an innate immune response that typically increases host resistance to infection. Yet CpG treatment reduces the resistance of normal mice to Candida albicans infection. This effect is mediated by CpG-induced interleukin-12, indicating that CpG-dependent cytokine production may have adverse consequences for the host.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|